New Limit's single-dose therapy reverses alcohol liver damage in old mice
One dose of mRNA therapy stops hangover and regenerates livers in old mice
Deep Dive
A cellular reprogramming therapy using mRNA encoding transcription factors, delivered via lipid nanoparticles (LNPs) — the same delivery technology used in COVID-19 vaccines — prevents new liver damage and helps the liver regenerate existing damage. Treated old mice no longer exhibit the severe hangover behavior (sedation, sleeping 8–12 hours) that untreated old mice display after alcohol exposure. Human trials are scheduled for next year in Australia.
Key Points
- Single dose of New Limit's mRNA-based therapy improved survival in old mice over months of repeated alcohol cycles
- Uses the same LNP delivery technology as Moderna and BioNTech COVID-19 vaccines
- Human trials scheduled to begin in Australia next year
Why It Matters
A potential first-in-class treatment for alcoholic liver disease using proven mRNA delivery, targeting both damage prevention and regeneration.